Indian pharmaceutical stocks are expected to remain in focus on Wednesday after US President Donald Trump announced a phased tariff roadmap for imported generic medicines, offering drugmakers a two-year duty-free window before imposing steep import levies.
The announcement comes as part of the US administration’s broader strategy to encourage pharmaceutical companies to shift manufacturing operations to the United States.